Xgeva Zytiga Combo

Denosumab (Xgeva) is an antibody injection that targets the RANK ligand and has shown to be effective against bone metastases. Xgeva is now licensed for treating metastatic cancer and Zytiga is licensed for treating metastatic prostate cancer so the combination of these 2 approaches can now be clinically evaluated. The 2 are compatible since Zytiga is taken once daily orally and Xgeva is given as a monthly injection. Combining Xgeva with Zytiga respresents a logical approach to treating metastatic prostate cancer and the results of using this combination in clinical practise will be interesting.